DK0501215T3 - Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillin - Google Patents
Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillinInfo
- Publication number
- DK0501215T3 DK0501215T3 DK92102197T DK92102197T DK0501215T3 DK 0501215 T3 DK0501215 T3 DK 0501215T3 DK 92102197 T DK92102197 T DK 92102197T DK 92102197 T DK92102197 T DK 92102197T DK 0501215 T3 DK0501215 T3 DK 0501215T3
- Authority
- DK
- Denmark
- Prior art keywords
- beta
- hutumab
- gluc
- fusion proteins
- glucuronidase
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4106389A DE4106389A1 (de) | 1991-02-28 | 1991-02-28 | Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0501215T3 true DK0501215T3 (da) | 2000-09-18 |
Family
ID=6426148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92102197T DK0501215T3 (da) | 1991-02-28 | 1992-02-10 | Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillin |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0501215B1 (fr) |
JP (1) | JP3524933B2 (fr) |
KR (1) | KR100249576B1 (fr) |
AT (1) | ATE193326T1 (fr) |
AU (1) | AU660445B2 (fr) |
CA (1) | CA2062047C (fr) |
DE (2) | DE4106389A1 (fr) |
DK (1) | DK0501215T3 (fr) |
ES (1) | ES2149159T3 (fr) |
GR (1) | GR3033708T3 (fr) |
IE (1) | IE920630A1 (fr) |
PT (1) | PT501215E (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4225853A1 (de) * | 1992-08-05 | 1994-02-10 | Behringwerke Ag | Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung |
DE4233152A1 (de) | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
DE4314556A1 (de) * | 1993-05-04 | 1994-11-10 | Behringwerke Ag | Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie |
EP0647450A1 (fr) * | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Prodrogues améliorées pour activation médiée par enzyme |
GB9324807D0 (en) * | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
DE19513676A1 (de) | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
SI0795334T1 (sl) * | 1996-03-12 | 2006-06-30 | Sanofi Aventis Deutschland | Predzdravila za zdravljenje tumorjev in vnetnih bolezni |
GB9709421D0 (en) * | 1997-05-10 | 1997-07-02 | Zeneca Ltd | Chemical compounds |
US6361774B1 (en) | 1999-09-17 | 2002-03-26 | Immunomedics, Inc. | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug |
ATE499115T1 (de) * | 1998-09-18 | 2011-03-15 | Immunomedics Inc | Antikörper verwiesene enzymprodrugtherapie mit glukuronidase |
US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
WO2005000902A1 (fr) * | 2003-06-30 | 2005-01-06 | Mu-Hyeon Choe | Dimere d'un recombinant chimere liant la fusion du groupe fonctionnel a domaine de liaison, forme via un pont a liaison disulfure, et ses procedes de production |
BR112019013189A2 (pt) | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT80662B (en) * | 1984-06-20 | 1986-12-09 | Sanofi Sa | Process to obtain anti-tumoral glycoprotein modified on its glycidic portions |
FR2591895B1 (fr) * | 1985-12-20 | 1988-08-26 | Sanofi Sa | Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques |
GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
DE3825615A1 (de) * | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
DE69019959T2 (de) * | 1989-01-23 | 1995-10-05 | Akzo Nobel Nv | Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln. |
DE3909799A1 (de) * | 1989-03-24 | 1990-09-27 | Behringwerke Ag | Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung |
JP3032287B2 (ja) * | 1989-12-11 | 2000-04-10 | イムノメデイツクス・インコーポレイテツド | 診断薬または治療薬の抗体ターゲティング |
DE4002888A1 (de) * | 1990-02-01 | 1991-08-08 | Behringwerke Ag | Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten |
-
1991
- 1991-02-28 DE DE4106389A patent/DE4106389A1/de not_active Withdrawn
-
1992
- 1992-02-10 DK DK92102197T patent/DK0501215T3/da active
- 1992-02-10 ES ES92102197T patent/ES2149159T3/es not_active Expired - Lifetime
- 1992-02-10 PT PT92102197T patent/PT501215E/pt unknown
- 1992-02-10 EP EP92102197A patent/EP0501215B1/fr not_active Expired - Lifetime
- 1992-02-10 AT AT92102197T patent/ATE193326T1/de active
- 1992-02-10 DE DE59209839T patent/DE59209839D1/de not_active Expired - Lifetime
- 1992-02-26 KR KR1019920002961A patent/KR100249576B1/ko not_active IP Right Cessation
- 1992-02-27 IE IE063092A patent/IE920630A1/en not_active IP Right Cessation
- 1992-02-27 AU AU11251/92A patent/AU660445B2/en not_active Expired
- 1992-02-28 JP JP07864492A patent/JP3524933B2/ja not_active Expired - Lifetime
- 1992-02-28 CA CA002062047A patent/CA2062047C/fr not_active Expired - Lifetime
-
2000
- 2000-06-16 GR GR20000401398T patent/GR3033708T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU660445B2 (en) | 1995-06-29 |
KR100249576B1 (ko) | 2000-03-15 |
DE4106389A1 (de) | 1992-09-03 |
ATE193326T1 (de) | 2000-06-15 |
EP0501215B1 (fr) | 2000-05-24 |
CA2062047A1 (fr) | 1992-08-29 |
EP0501215A3 (en) | 1993-08-11 |
IE920630A1 (en) | 1992-09-09 |
EP0501215A2 (fr) | 1992-09-02 |
AU1125192A (en) | 1993-01-28 |
ES2149159T3 (es) | 2000-11-01 |
GR3033708T3 (en) | 2000-10-31 |
JPH07179500A (ja) | 1995-07-18 |
PT501215E (pt) | 2000-10-31 |
DE59209839D1 (de) | 2000-06-29 |
JP3524933B2 (ja) | 2004-05-10 |
CA2062047C (fr) | 2007-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK371089A (da) | Antigenkonstruktioner, deres fremstilling og anvendelse | |
DK0501215T3 (da) | Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillin | |
ATE316982T1 (de) | Mehrere zytokin-antikörper komplexen | |
EP0683234A4 (fr) | ANTICORPS DIRIGE CONTRE LE -g(b)-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION. | |
ATE192457T1 (de) | Trivalent monospezifische antigen-bindende proteine | |
ATE204480T1 (de) | Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon | |
NO961115L (no) | Humane metabotrope glutamatreseptorsubtyper (HMR4, HMR6, HMR7) og relaterte DNA forbindelser | |
FI952720A0 (fi) | Kasvainten vastaisten metyylitrioyhdisteiden konjugaatteja ja välituotteita niiden synteesiä varten | |
ATE304371T1 (de) | Verwendung von staphylococcus enterotoxin homologe für krebs-therapie | |
DE69317886D1 (de) | Neue propoxyphenderivate sowie deren protein-und polypeptidlabels und-konjugate | |
CA2126182A1 (fr) | Anticorps humanises reagissant avec le gpiib/iiia | |
DK0585570T3 (da) | Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse | |
DE59105603D1 (de) | Monoklonale antikörper gegen den interleukin 2-rezeptor. | |
DK0513565T3 (da) | Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse | |
DK0656906T3 (da) | Endothelcellemolekyle, der medierer lymfocytbinding i mennesket | |
ES2076238T3 (es) | Adnc que codifica la proteina 9 de placenta (pp9), su aislamiento y utilizacion. | |
CY1114280T1 (el) | Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας | |
BRPI9715268B8 (pt) | preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção | |
ATE95426T1 (de) | Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper. |